- Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: HIV Infection
Intervention: Other: monetary reinforcer
Sponsors: University of British Columbia; University of British Columbia; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCondition: Hepatitis C, Chronic
Interventions: Drug: tenofovir; Drug: ribavirin; Drug: ribavirin; Drug: ribavirin; Drug: caffeine; Drug: caffeine; Drug: midazolam; Drug: midazolam; Drug: tolbutamide; Drug: tolbutamide; Drug: pegylated inteferon; Drug: pegylated interferon; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Other: Submaximal exercises
Sponsors: Laval University; Laval University
Recruiting - verified January 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Smoking Cessation
Interventions: Behavioral: Ottawa Model with SmartCard; Behavioral: Usual care
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; University of Ottawa Heart Institute
Recruiting - verified December 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Opioid Dependence; Heroin Dependence
Interventions: Drug: Hydromorphone, Injectable; Drug: Diacetylmorphine, injectable; Drug: Hydromorphone, liquid oral; Drug: Diacetylmorphine, liquid oral
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR); Providence HealthCare
Not yet recruiting - verified October 2011 - Condition: Smoking
Interventions: Drug: Nicotine replacement therapy; Other: No intervention
Sponsors: Centre for Addiction and Mental Health; Centre for Addiction and Mental Health; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Device: Ventripoint Medical System
Sponsors: VentriPoint Diagnostics Ltd.; VentriPoint Diagnostics Ltd.
Recruiting - verified April 2012 - Condition: Malignant Lymphoma, Stem Cell Type
Interventions: Drug: Plerixafor (Mozobil); Drug: Plerixafor + G-CSF
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Genzyme
Not yet recruiting - verified July 2011 - Condition: Squamous Cell Carcinoma of Anal Canal
Interventions: Drug: Nimotuzumab; Radiation: Intensity Modulated Radiation Therapy (IMRT)
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Dr. Te Vuong; YM BioSciences
Recruiting - verified May 2012 - Condition: Urinary Incontinence
Interventions: Drug: solifenacin succinate; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012 - Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified February 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV Infection
Interventions: Drug: atazanavir; Drug: atazanavir/ritonavir
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified September 2011 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL
Intervention: Drug: Plerixafor Dose Escalation
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Condition: Glaucoma
Interventions: Device: portable CCTV; Device: Telescopes, telemicroscopes and microscopes; Device: Absorptive filters
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Pfizer
Recruiting - verified August 2011 - Conditions: Nutrition Assessment; Obesity
Intervention: Behavioral: Portion Size Measurement Aids (PSMAs)
Sponsors: University of Alberta; University of Alberta
Recruiting - verified April 2012 - Condition: HIV-1
Interventions: Drug: lersivirine; Drug: lersivirine; Drug: efavirenz; Drug: lersivirine; Drug: lersivirine; Drug: etravirine
Sponsors: Pfizer; Pfizer; ViiV Healthcare
Recruiting - verified May 2012 - Conditions: HIV; Hepatitis C; Liver Fibrosis
Interventions: Drug: Raltegravir; Drug: Ritonavir-boosted protease inhibitor
Sponsors: McGill University Health Center; McGill University Health Center; Merck; Canadian HIV Trials Network
Recruiting - verified March 2012 - Condition: Cervical Spondylotic Myelopathy
Interventions: Drug: riluzole; Drug: Placebo medication
Sponsors: SpineNet; SpineNet
Recruiting - verified April 2012 - Conditions: Anorexia; Cancer Cachexia
Intervention: Drug: OHR/AVR118
Sponsors: Ohr Pharmaceutical Inc.; Ohr Pharmaceutical Inc.
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim) plus Plerixafor Injection; Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors: Genzyme; Genzyme
Recruiting - verified April 2012 - Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified November 2011 - Conditions: Multiple Myeloma; Lymphoma
Interventions: Drug: Plerixafor; Other: Observation: Nonintervention
Sponsors: CancerCare Manitoba; CancerCare Manitoba
Recruiting - verified February 2012 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Behavioral: Aerobic exercise; Behavioral: Usual care
Sponsors: Hopital du Sacre-Coeur de Montreal; Hopital du Sacre-Coeur de Montreal; McGill University Health Center
Recruiting - verified October 2011 - Conditions: Hypercholesterolemia; HIV Infections
Interventions: Drug: Ezetimibe; Drug: Rosuvastatin (standard care)
Sponsors: University of British Columbia; University of British Columbia; Merck Frosst-Schering Pharma, G.P.
Recruiting - verified November 2011 - Condition: HIV Infections
Intervention:
Sponsors: Radboud University; Radboud University; PENTA Foundation; Merck; Bristol-Myers Squibb; CIHR Canadian HIV Trials Network
Recruiting - verified May 2012 - Condition: HIV Infection
Interventions: Dietary Supplement: Micronutrients and antioxidants; Dietary Supplement: Multivitamins and minerals
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian HIV Trials Network; Ontario HIV Treatment Network
Recruiting - verified July 2011 - Condition: Bacterial Vaginosis
Interventions: Drug: Gelatin; Drug: Boric acid; Drug: Metronidazole
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012 - Condition: Pulmonary Tuberculosis
Interventions: Drug: rifampin; Drug: rifapentine; Drug: rifapentine; Drug: rifapentine
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Hepatitis C Virus Infection
Interventions: Drug: Interferon injections and ribavirin; Drug: Interferon injections and ribavirin
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified November 2011 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified February 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Join Clinical Trials in Mobile,Alabama |
